Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$73.80-3.3%$69.95$54.11▼$89.98$29.46B1.454.41 million shs3.55 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+1.85%+5.48%+1.30%+21.29%-8.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$73.80-3.3%$69.95$54.11▼$89.98$29.46B1.454.41 million shs3.55 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+1.85%+5.48%+1.30%+21.29%-8.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.89Moderate Buy$84.8815.02% UpsideCurrent Analyst Ratings BreakdownLatest DXCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026DXCMDexCom Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/23/2026DXCMDexCom BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026DXCMDexCom Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$86.006/15/2026DXCMDexCom Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.00 ➝ $88.006/10/2026DXCMDexCom UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.006/10/2026DXCMDexCom TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $95.006/9/2026DXCMDexCom MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$75.00 ➝ $85.006/8/2026DXCMDexCom Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$91.006/5/2026DXCMDexCom Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$85.00 ➝ $90.006/1/2026DXCMDexCom Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.66B6.11$2.73 per share27.07$7.04 per share10.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$836.30M$2.3432.6324.201.2319.31%33.33%13.19%7/30/2026 (Confirmed)Latest DXCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026DXCMDexCom$0.61N/AN/AN/A$1.29 billionN/A4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.421.951.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom11,000385.87 million384.79 millionOptionableDXCM HeadlinesRecent News About These Companies1 Mid-Cap Stock to Target This Week and 2 We Find Risky1 hour ago | finance.yahoo.comTeachers Retirement System of The State of Kentucky Acquires 72,700 Shares of DexCom, Inc. $DXCM3 hours ago | marketbeat.comDexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with DiabetesJuly 13 at 5:06 PM | finance.yahoo.comDexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with DiabetesJuly 13 at 5:00 PM | businesswire.comDexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 12 at 4:43 PM | marketbeat.comKornitzer Capital Management Inc. KS Sells 22,660 Shares of DexCom, Inc. $DXCMJuly 12 at 12:47 PM | marketbeat.comSumitomo Mitsui Trust Group Inc. Reduces Stock Holdings in DexCom, Inc. $DXCMJuly 12 at 12:39 PM | marketbeat.comContrasting DexCom (NASDAQ:DXCM) and Orthofix Medical (NASDAQ:OFIX)July 11 at 10:55 AM | americanbankingnews.comIs DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift?July 10, 2026 | finance.yahoo.comDexcom (DXCM) Receives a Buy from CitiJuly 10, 2026 | theglobeandmail.comInvestors’ Confidence in DexCom (DXCM) Rises as Growth Outlook ReassuredJuly 9, 2026 | finance.yahoo.comDexCom slips as investors appear to pause ahead of earnings and product transitionJuly 9, 2026 | quiverquant.comQDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern TimeJuly 9, 2026 | finance.yahoo.comHeald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM UsersJuly 9, 2026 | finance.yahoo.comDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern TimeJuly 9, 2026 | businesswire.comKevin Sayer Sells 26,756 Shares of DexCom (NASDAQ:DXCM) StockJuly 9, 2026 | americanbankingnews.comDSM Capital Partners LLC Has $120.82 Million Holdings in DexCom, Inc. $DXCMJuly 9, 2026 | marketbeat.comGlucotrack Clears Key Milestone to Commercialize Its Implantable CGMJuly 8, 2026 | finance.yahoo.comHere's Why DexCom (DXCM) is a Strong Growth StockJuly 8, 2026 | zacks.comInsider Selling: DexCom (NASDAQ:DXCM) Insider Sells 26,756 Shares of StockJuly 8, 2026 | insidertrades.comInsulet launches Omnipod 5 in SpainJuly 7, 2026 | medtechdive.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 20263 Non-Pharma Firms That Could Benefit From the GLP-1 TrendBy Nathan Reiff | June 20, 2026DXCM Company DescriptionsDexCom NASDAQ:DXCM$73.80 -2.55 (-3.34%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Fission for Profits: Unlocking America’s Uranium Vault The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
